Third agreement signed for antibody platform

20 January 2020

Scancell Holdings plc

("Scancell" or the "Company")

Momentum growing with Scancell antibody platform as third agreement signed

Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a collaboration and non-exclusive research agreement with a US-based, clinical stage antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) including those that have been enhanced with Scancell's proprietary AvidiMab™ technology.

This is the third collaboration agreement evaluating Scancell's pipeline of anti-TaG mAbs that have been engineered using the Company's AvidiMab™ technology; conferring these mAbs with the ability to directly kill tumour cells. Today's announcement follows prior agreements announced in September 2019 and December 2019.

TaGs are glycan motifs that are associated with tumour malignancies and these can be targeted by antibodies, including antibody drug conjugates (ADC) and also adoptive cell therapies such as chimeric antigen receptor (CAR) T cells.

Under the terms of the collaboration and research agreement, this new collaboration partner will conduct preclinical studies to evaluate Scancell's anti-TaG mAbs for the treatment of cancer.

Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:

"This continued momentum with AvidiMab™ and our tumour-associated glycan antibodies demonstrates the growing excitement around this platform. This is another important collaboration for Scancell and illustrates the future value that this third platform could potentially generate for the Company."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For Further Information:

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·       SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·       SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For further details, please see our website:  www.scancell.co.uk